| 序号 | 持有人姓名/名称 | 持股数量（股） | 占总股本的比例（%） | | --- | --- | --- | --- | | 1 | 刘革新 | 379128280 | 23.72 | | 2 | 雅安市国有资产经营有限责任公司 | 96983174 | 6.07 | | 3 | 中国工商银行股份有限公司－中欧医疗健康混合型 | 38195361 | 2.39 | | | 证券投资基金 | | | | 4 | 香港中央结算有限公司 | 37208350 | 2.33 | | 5 | 中国建设银行股份有限公司－工银瑞信前沿医疗股 | 22000000 | 1.38 | | | 票型证券投资基金 | | | | 6 | 中国工商银行股份有限公司－华泰柏瑞沪深300 交易 | 18460038 | 1.16 | | | 型开放式指数证券投资基金 | | | | 7 | #刘亚光 | 15119962 | 0.95 | | 8 | 中国建设银行股份有限公司－易方达沪深300医药卫 | 14908121 | 0.93 | 证券代码：002422 证券简称：科伦药业 公告编号：2026-005 四川科伦药业股 ...

四川科伦药业股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）第八届董 事会第十一次会议通知于 2026 年 1 月 2 日以电话和电子邮件方式送达全体董事 和高级管理人员。第八届董事会第十一次会议于 2026 年 1 月 4 日以通讯的方式 召开，会议应到董事 9 人，实到董事 9 人，公司高级管理人员列席了会议。会议 的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行 政法规、部门规章、规范性文件和《公司章程》的规定，作出的决议合法有效。 本次会议由公司董事长刘革新先生主持，与会董事就以下议案进行了审议与 表决，形成了如下决议： 一、逐项审议通过了《关于回购公司股份方案的议案》 （一）拟回购股份的目的及用途 基于对公司价值的高度认可和对公司未来发展前景的信心，结合公司股价近 期的表现，为增强投资者对公司的信心，公司拟以自有资金通过集中竞价交易方 式进行股份回购。 证券代码：002422 证券简称：科伦药业 公告编号：2026-003 ...

科伦药业公告称，公司第八届董事会第十一次会议审议通过回购股份方案。公司拟以自有资金，通过集 中竞价交易方式回购股份，用于员工持股计划或股权激励，若未能在回购完成后规定时间内使用则注 销。回购资金不低于5000万元且不超过1亿元，回购价不超规定上限，预计可回购股份占总股本 0.09%-0.18%。回购期限自董事会通过方案之日起12个月内，公司董事会授权管理层办理相关事项。 ...

科伦药业公告，拟以5000万元-1亿元回购公司股份，回购价格不超过35元/股。 ...

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.01% on January 5, 2025, and a total market capitalization of 478.46 billion yuan [1] - As of January 5, 2025, the stock price is reported at 29.94 yuan per share, with a trading volume of 1.64 billion yuan and a turnover rate of 0.43% [1] - The company has experienced a year-to-date stock price increase of 2.01%, but has seen declines of 1.77% over the last five trading days, 12.20% over the last 20 days, and 16.68% over the last 60 days [1] Group 2 - For the period from January to September 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, representing a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, the number of shareholders for Kelun Pharmaceutical increased to 37,100, marking an 8.35% rise from the previous period, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings for several institutional investors, such as China Europe Medical Health Mixed Fund and Industrial Bank Frontier Medical Stock A [3]

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., has received breakthrough therapy designation from the National Medical Products Administration of China for its ADC drug targeting TROP2 in combination with Merck's PD-1 monoclonal antibody for treating specific types of non-small cell lung cancer (NSCLC) [1] Group 1 - Kelong Pharmaceutical announced that its subsidiary Kelong Botai's ADC drug, Lukanosatuzumab, has been granted breakthrough therapy designation for first-line treatment of PD-L1 tumor proportion score (TPS) ≥ 1% in EGFR gene mutation-negative and ALK-negative locally advanced or metastatic NSCLC [1] - The company also reported that its ADC drug SKB105 (also known as CR-003), targeting integrin β6, has received approval for clinical trials from the National Medical Products Administration for the treatment of advanced solid tumors [1]

2025年12月 ，科伦博泰与 Crescent Biopharma, Inc. ("Crescent ")就SKB105/CR-003 与 SKB118 (程序性细 胞死亡蛋白-1(PD-1) x 血管内皮生长因子(VEGF)双特异性抗体，亦称 CR-001)达成战略合作，其中科伦 博泰授予Crescent 在美国、欧洲及所有其他大中华地区以外市场研究、开发、生产和商业化 SKB105/CR-003 的独家权 利，Crescent 则授予科伦博泰在大中华地区研究、开发、生产和商业化 SKB118/CR-001 的独家权利。 科伦博泰计划于近期向中国国家药品监督管理局药品审评中心递交SKB118/CR-001的IND申请。 格隆汇1月5日丨科伦药业(002422.SZ)公布，四川科伦药业股份有限公司(以下简称"公司")近日获悉，公 司控股子公司四川科伦博泰生物医药股份有限公司(以下简称"科伦博泰")自主研发的靶向整合素β6 (ITGB6)抗体偶联药物(ADC) SKB105(亦称CR-003)的新药临床试验(IND)申请已获中国国家药品监督管 理局(NMPA)药品审评中心(CDE)批准，用于治疗晚期实体瘤。 ...

Core Viewpoint - The company, Kelun Pharmaceutical, has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China for its antibody-drug conjugate (ADC) SKB264/MK-2870, in combination with Merck's PD-1 monoclonal antibody, for the treatment of specific types of non-small cell lung cancer (NSCLC) [1]. Group 1 - Kelun Pharmaceutical's subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., is involved in the development of the ADC targeting TROP2 [1]. - The combination therapy is aimed at patients with locally advanced or metastatic NSCLC who are negative for EGFR gene mutations and ALK [1]. - The therapy is specifically for patients with a tumor proportion score (TPS) of ≥1% for PD-L1 [1].

2025年12月，科伦博泰与 Crescent Biopharma, Inc. ("Crescent")就 SKB105/CR-003 与 SKB118 (程序性细 胞死亡蛋白-1(PD-1) x 血管内皮生长因子 (VEGF)双特异性抗体，亦称CR-001)达成战略合作，其中科伦 博泰授予Crescent 在美国、欧洲及所有其他大中华地区(包括中国内地、香港、澳门及台湾)以外市场研 究、开发、生产和商业化SKB105/CR-003的独家权利，Crescent则授予科伦博泰在大中华地区研究、开 发、生产和商业化SKB118/CR-001的独家权利。科伦博泰计划于近期向中国国家药品监督管理局药品审 评中心递交 SKB118/CR-001 的 IND 申请。 智通财经APP讯，科伦药业(002422.SZ)发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医 药股份有限公司(以下简称"科伦博泰")自主研发的靶向整合素β6(ITGB6)抗体偶联药物(ADC)SKB105(亦 称 CR-003)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)批准， 用于治疗晚期实体瘤。 ...